FDA approves BMS’ Opdivo and Yervoy combination in first-line mesotheliomaBristol-Myers Squibb’s immunotherapy combination of Opdivo and Yervoy has been approved in the US in a new indication Share XFDA approves BMS’ Opdivo and Yervoy combination in first-line mesotheliomahttps://pharmaphorum.com/news/fda-approves-bms-opdivo-and-yervoy-combination-in-first-line-mesothelioma/
BMS’ Opdivo aces trial in asbestos-linked lung cancerBristol-Myers Squibb’s Opdivo has improved survival in a trial involving patients with mesothelioma, a form of lung cancer, Share XBMS’ Opdivo aces trial in asbestos-linked lung cancerhttps://pharmaphorum.com/news/bms-opdivo-aces-trial-in-asbestos-linked-lung-cancer/
Owkin’s machine learning tech to inform mesothelioma trialsA mesothelioma prognostic model from medical machine learning firm Owkin has been showcased in the journal Nature, and Share XOwkin’s machine learning tech to inform mesothelioma trialshttps://pharmaphorum.com/news/owkins-machine-learning-tech-gives-mesothelioma-prognosis-and-survival-insights/
BI drug named Promising Innovative Medicine in mesotheliomaBoehringer Ingelheim is the latest company to gain a Promising Innovative Medicine (PIM) status in the UK for Share XBI drug named Promising Innovative Medicine in mesotheliomahttps://pharmaphorum.com/news/bi-drug-named-promising-innovative-medicine-mesothelioma/
